

Our carrier screening options



Learn more at eugene.to/learn

Test	Core	Comprehensive	Couples (Expanded)
Genes included	3 genes (CFTR, SMN and FMR1)	787 genes (View full gene list)	620+ genes (View full gene list)
Who	Biological females screened first, male reproductive partner only screened if female is a carrier of CFTR on SMN	For individuals, reproductive couples and those using donor gametes	Reproductive couples (male–female only)
Turn around time	Up to 4 weeks Sequential testing of male partner adds 2 weeks to TAT	Up to 4 weeks	6–8 weeks If either partners' sample fails + 6–8 weeks for recollection. No individual reporting available unless testing is completed
Cost	\$0 Medicare eligibility required*	\$949 \$1499 Individual Couple	\$949 \$949 is the out of pocket cost Medicare eligibility required*
When	RANZCOG & RACGP guidelines recommend that all couples planning pregnancy or in 1st trimester should be offered carrier screening		
Reporting	 Individual carrier status Limitation: only common gene variants are included in this assessment. 	 Individual carrier status for all conditions Secondary finding with potential personal implications. Reproductive risk (low, increased risk) 	 Reproductive risk (low or increased risk) NB. Individual carrier results for CF, SMA and FXS for female only
Conditions	Cystic fibrosis (CF), spinal muscular atrophy (SMA) and fragile X syndrome (FXS)	 Screens for 100s of genetic conditions relevant to more ethnicities. Includes conditions that may have severe presentations (cognitive or physical impairments), early childhood onset, or for which early intervention may be beneficial Full sequencing of CF, SMA and FXS 	 Screens for 100s of genetic conditions relevant to more ethnicities Focuses on severe childhood onset conditions Screening for common causes of CF, SMA and FXS
Pick up rates of at-risk couples	1 in 240 couples will be at increased risk (0.42%)	1 in 50 couples will be at increased risk when screened for over 750 conditions (~2%)	1 in 40 couples will be identified at increased risk (2–3%)